Key result
An elimination strategy utilizing targeted mass testing and phylogenetic analysis achieved suppression of COVID-19 morbidity and mortality regardless of vaccine availability.
Why the study?
Mitigation strategies with vaccination carry the risk of uncontrollable endemics of future SARS-CoV-2 variants resistant to vaccine-induced immunity, unlike elimination strategies.
Does targeted mass testing and phylogenetic analysis prevent community transmission of SARS-CoV-2 beta variant compared to a mitigation strategy with vaccination?
Does targeted mass testing and phylogenetic analysis prevent community transmission of SARS-CoV-2 beta variant compared to a mitigation strategy with vaccination?
An elimination strategy using targeted mass testing and phylogenetic analysis may effectively suppress COVID-19 morbidity and mortality compared to mitigation strategies relying solely on vaccination.
Supports targeted testing and phylogenetics for COVID-19 suppression in low-vaccine settings; leaves open superiority over mitigation in prospective trials.
As of 9 September 2021, some areas of the Western Pacific region, such as China, Taiwan, and New Zealand, maintained their elimination strategy to minimize community incidence of SARS‐CoV‐2 infection. Even during the early vaccination phase of the pandemic, these areas had achieved suppression of the COVID-19 morbidity and mortality regardless of vaccine availability.1 On the other hand, the mitigation strategy with vaccination, which was employed by many other countries, has potential risk of a uncontrollable endemic of future variants with high resistance to vaccine-induced immunity.
No takes yet. Share an insight, caveat, or question.
Tokuda et al. (2022) studied SARS-CoV-2 infection. Elimination strategy (targeted mass testing and phylogenetic analysis) vs. Mitigation strategy with vaccination was evaluated. An elimination strategy utilizing targeted mass testing and phylogenetic analysis achieved suppression of COVID-19 morbidity and mortality regardless of vaccine availability.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: